KromaTiD and SeQure Dx Ink Pact For Cell and Gene Therapy Research

KromaTiD and SeQure Dx announced a collaboration to commercialize a complete and integrated study of off-target gene editing in support of cell and gene therapy research, IND applications, and medicinal product development. 

The combination of SeQure Dx's NoteSeQ™and ScopeSeQ™ platforms with KromaTiD's dGH in-Site™, dGH SCREEN™ and Genomic Integrity Karyotyping™ services provides the world's first comprehensive, one-stop gene editing evaluation solution, as per KromaTiD.

Dr. Keith Joung, Scientific Founder of SeQure Dx, states, "This joint offering provides a package that will empower scientists to predict and measure outcomes of gene editing across multiple platforms with the goal of minimizing risks to patients from the design stages and ultimately into the clinic."

Dr. Douglas Smith, Sr. VP Research & Development at SeQure Dx, states, "This partnership creates a powerful solution for developers of genome editing therapies by combining SeQure's best in class off-target nomination and confirmation platforms with Kromatid's superior technologies for unbiased genome-wide rearrangement detection."

KromaTiD has created a suite of commercial products and services that provide cell and gene therapy developers with unique assays for off-target editing, transgene insertion, and edit-associated structural variation. "By using the power of SeQure Dx's predictive, personalized ONE-seq bioinformatics to design our dGH in-Site assays, researchers can not only confirm the outcomes of gene editing in the genome most relevant to the patient population", says Christopher Tompkins, KromaTiD's Chief Technology Officer. "They can then use this data to optimize their editing system, reduce off-target effects, and ultimately improve the safety of the drug product for the benefit of patients."